Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPPHIRE: Cleminorexton in Narcolepsy Type 1 and Type 2
NCT07598708Phase 3Recruiting
- Sponsor
- Centessa Pharmaceuticals
- Start
- May 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cleminorexton in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), sponsored by Centessa Pharmaceuticals. Started May 2026; status: recruiting.
02
Drugs
cleminorexton
03
Conditions
narcolepsy type 1 (NT1)narcolepsy type 2 (NT2)
Beyond the preview
Go deeper on NCT07598708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07598708.